Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2019 18:17 ET | Source: Mesoblast Limited

Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy

MELBOURNE, Australia and NEW YORK and BASEL, Switzerland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast (ASX:MSB; Nasdaq:MESO) and Lonza (SWX: LONN) announced today that they have entered into an...
October 03, 2019 07:59 ET | Source: Mesoblast Limited

Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a...
September 09, 2019 19:40 ET | Source: Mesoblast Limited

Mesoblast Corporate Update: Analyst Call

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an...
September 09, 2019 19:38 ET | Source: Mesoblast Limited

Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in...
August 29, 2019 17:50 ET | Source: Mesoblast Limited

Mesoblast Reports 2019 Full Year Results

NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported strong operational progress and financial highlights for the fourth...
August 27, 2019 18:36 ET | Source: Mesoblast Limited

Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to...
August 27, 2019 06:00 ET | Source: Mesoblast Limited

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD

NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, announced today positive...
August 14, 2019 06:00 ET | Source: Mesoblast Limited

Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial

NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it intends to provide its...
August 12, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr...
July 31, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Quarterly Cash Flow Report

MELBOURNE, Australia and NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its operational highlights and its quarterly cash flows for the fourth...

keyboard_arrow_left Previous Page